

DAFTAR PUSTAKA

Chopski, S. G. *et al.* (2019) 'Mechanical circulatory support of the right ventricle for adult and pediatric patients with heart failure', *ASAIO Journal*, 65(2), pp. 106–116. doi: 10.1097/MAT.0000000000000815.

Dharmarajan, K. and Rich, M. W. (2017) 'Epidemiology, Pathophysiology, and Prognosis of Heart Failure in Older Adults', *Heart Failure Clinics*. Elsevier Inc, 13(3), pp. 417–426. doi: 10.1016/j.hfc.2017.02.001.

FKUI (2007) *Farmakologi dan Terapi edisi 5*. 5th edn. Edited by S. G. Gunawan. Badan Penerbit FKUI.

Heidenreich, P. A. *et al.* (2022) *2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines*, *Circulation*. doi: 10.1161/CIR.0000000000001063.

Hundemer, G. L. and Sood, M. M. (2021) 'Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management', *Pharmacological Research*. Elsevier Ltd, 172(August), p. 105835. doi: 10.1016/j.phrs.2021.105835.

James, S. L. *et al.* (2018) 'Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017', *The Lancet*, 392(10159), pp. 1789–1858. doi: 10.1016/S0140-6736(18)32279-7.

Laurent, S. (2017) 'Antihypertensive drugs', *Pharmacological Research*. Elsevier Ltd, 124, pp. 116–125. doi: 10.1016/j.phrs.2017.07.026.

Law, S. P. *et al.* (2021) 'Right heart failure considerations in pediatric ventricular assist devices', *Pediatric Transplantation*, 25(3), pp. 1–9. doi: 10.1111/ptr.13990.

McDonagh, T. A. *et al.* (2021) '2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure', *European Heart Journal*, 42(36), pp. 3599–3726. doi: 10.1093/eurheartj/ehab368.

Messerli, F. H. *et al.* (2018) 'Angiotensin-Converting Enzyme Inhibitors in

Hypertension: To Use or Not to Use?', *Journal of the American College of Cardiology*. Elsevier, 71(13), pp. 1474–1482. doi: 10.1016/j.jacc.2018.01.058.

Page, M. J. *et al.* (2021) 'The PRISMA 2020 statement: An updated guideline for reporting systematic reviews', *The BMJ*, 372. doi: 10.1136/bmj.n71.

PERKI (2020) 'Pedoman Tatalaksana Gagal Jantung 2020. 2nd ed.', *Perhimpunan Dokter Spesialis Kardiovaskular Indonesia 2020*, 6(11), pp. 951–952.

Ponikowski, P. *et al.* (2014) 'Heart failure: preventing disease and death worldwide', *ESC Heart Failure*, 1(1), pp. 4–25. doi: 10.1002/ehf2.12005.

'PRISMA Flow Chart' (2020).

Pusat Data dan Informasi Kementerian Kesehatan RI (2017) *Profil Penyakit Tidak Menular, Journal of Chemical Information and Modeling*.

Rachamin, Y. *et al.* (2021) 'Heart failure epidemiology and treatment in primary care: a retrospective cross-sectional study', *ESC Heart Failure*, 8(1), pp. 489–497. doi: 10.1002/ehf2.13105.

Raebel, M. A. (2012) 'Hyperkalemia Associated with Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers', *Cardiovascular Therapeutics*, 30(3), pp. 156–166. doi: 10.1111/j.1755-5922.2010.00258.x.

Roger, V. L. (2021) 'Epidemiology of Heart Failure A Contemporary Perspective', pp. 1421–1434. doi: 10.1161/CIRCRESAHA.121.318172.

Skrzynia, C. *et al.* (2014) 'Genetics and Heart Failure: A Concise Guide for the Clinician', *Current Cardiology Reviews*, 11(1), pp. 10–17. doi: 10.2174/1573403x09666131117170446.

Yunus, N. *et al.* (2020) 'GAMBARAN PEMBERIAN ACE INHIBITOR ATAU ANGIOTENSIN RECEPTOR BLOCKER PADA PASIEN GAGAL JANTUNG', pp. 311–322.